nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—GSTP1—amyotrophic lateral sclerosis	0.571	1	CbGaD
Clomipramine—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.124	1	CbGbCtD
Clomipramine—Schizophreniform disorder—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0675	CcSEcCtD
Clomipramine—Schizophrenic reaction—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0675	CcSEcCtD
Clomipramine—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.00817	0.159	CbGeAlD
Clomipramine—Vestibular disorder—Riluzole—amyotrophic lateral sclerosis	0.00551	0.0242	CcSEcCtD
Clomipramine—Alveolitis allergic—Riluzole—amyotrophic lateral sclerosis	0.00424	0.0186	CcSEcCtD
Clomipramine—Salivary gland enlargement—Riluzole—amyotrophic lateral sclerosis	0.00398	0.0175	CcSEcCtD
Clomipramine—Uterine haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0139	CcSEcCtD
Clomipramine—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.00297	0.0131	CcSEcCtD
Clomipramine—Hypoventilation—Riluzole—amyotrophic lateral sclerosis	0.00297	0.0131	CcSEcCtD
Clomipramine—Hyperacusis—Riluzole—amyotrophic lateral sclerosis	0.00297	0.0131	CcSEcCtD
Clomipramine—Pyelonephritis—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0128	CcSEcCtD
Clomipramine—Manic psychosis—Riluzole—amyotrophic lateral sclerosis	0.0028	0.0123	CcSEcCtD
Clomipramine—Yawning—Riluzole—amyotrophic lateral sclerosis	0.00275	0.0121	CcSEcCtD
Clomipramine—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0114	CcSEcCtD
Clomipramine—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00964	CcSEcCtD
Clomipramine—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00213	0.0414	CbGeAlD
Clomipramine—HTR2A—pons—amyotrophic lateral sclerosis	0.0021	0.0409	CbGeAlD
Clomipramine—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00925	CcSEcCtD
Clomipramine—Hostility—Riluzole—amyotrophic lateral sclerosis	0.002	0.00879	CcSEcCtD
Clomipramine—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.002	0.00879	CcSEcCtD
Clomipramine—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00857	CcSEcCtD
Clomipramine—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00857	CcSEcCtD
Clomipramine—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00837	CcSEcCtD
Clomipramine—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00827	CcSEcCtD
Clomipramine—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00809	CcSEcCtD
Clomipramine—SLC6A2—nerve—amyotrophic lateral sclerosis	0.00181	0.0353	CbGeAlD
Clomipramine—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00791	CcSEcCtD
Clomipramine—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00179	0.0349	CbGeAlD
Clomipramine—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00774	CcSEcCtD
Clomipramine—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00766	CcSEcCtD
Clomipramine—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0075	CcSEcCtD
Clomipramine—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00742	CcSEcCtD
Clomipramine—ADRA2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00165	0.032	CbGeAlD
Clomipramine—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00721	CcSEcCtD
Clomipramine—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00714	CcSEcCtD
Clomipramine—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00714	CcSEcCtD
Clomipramine—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00714	CcSEcCtD
Clomipramine—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00707	CcSEcCtD
Clomipramine—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00694	CcSEcCtD
Clomipramine—Delusion—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00687	CcSEcCtD
Clomipramine—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00687	CcSEcCtD
Clomipramine—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00681	CcSEcCtD
Clomipramine—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00154	0.0301	CbGeAlD
Clomipramine—HTR2A—appendage—amyotrophic lateral sclerosis	0.00154	0.03	CbGeAlD
Clomipramine—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00675	CcSEcCtD
Clomipramine—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00675	CcSEcCtD
Clomipramine—Mania—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00669	CcSEcCtD
Clomipramine—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00657	CcSEcCtD
Clomipramine—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00652	CcSEcCtD
Clomipramine—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00646	CcSEcCtD
Clomipramine—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00646	CcSEcCtD
Clomipramine—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00635	CcSEcCtD
Clomipramine—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00625	CcSEcCtD
Clomipramine—Clobazam—SLC6A1—amyotrophic lateral sclerosis	0.00141	0.554	CrCbGaD
Clomipramine—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.0014	0.0272	CbGeAlD
Clomipramine—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00605	CcSEcCtD
Clomipramine—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00605	CcSEcCtD
Clomipramine—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00136	0.006	CcSEcCtD
Clomipramine—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00136	0.006	CcSEcCtD
Clomipramine—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00587	CcSEcCtD
Clomipramine—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00566	CcSEcCtD
Clomipramine—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00558	CcSEcCtD
Clomipramine—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00554	CcSEcCtD
Clomipramine—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00535	CcSEcCtD
Clomipramine—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00535	CcSEcCtD
Clomipramine—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00531	CcSEcCtD
Clomipramine—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00528	CcSEcCtD
Clomipramine—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00524	CcSEcCtD
Clomipramine—Gout—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00521	CcSEcCtD
Clomipramine—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00514	CcSEcCtD
Clomipramine—GSTP1—embryo—amyotrophic lateral sclerosis	0.00116	0.0226	CbGeAlD
Clomipramine—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00498	CcSEcCtD
Clomipramine—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00495	CcSEcCtD
Clomipramine—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00495	CcSEcCtD
Clomipramine—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00486	CcSEcCtD
Clomipramine—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00486	CcSEcCtD
Clomipramine—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00486	CcSEcCtD
Clomipramine—HTR2A—nerve—amyotrophic lateral sclerosis	0.00109	0.0212	CbGeAlD
Clomipramine—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0047	CcSEcCtD
Clomipramine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00107	0.0047	CcSEcCtD
Clomipramine—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00457	CcSEcCtD
Clomipramine—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00447	CcSEcCtD
Clomipramine—Coma—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00444	CcSEcCtD
Clomipramine—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000969	0.00426	CcSEcCtD
Clomipramine—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00422	CcSEcCtD
Clomipramine—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00095	0.00418	CcSEcCtD
Clomipramine—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.000941	0.00414	CcSEcCtD
Clomipramine—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.000941	0.00414	CcSEcCtD
Clomipramine—HTR2C—brainstem—amyotrophic lateral sclerosis	0.000933	0.0182	CbGeAlD
Clomipramine—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000923	0.00406	CcSEcCtD
Clomipramine—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.000923	0.00406	CcSEcCtD
Clomipramine—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.000914	0.00402	CcSEcCtD
Clomipramine—Deafness—Riluzole—amyotrophic lateral sclerosis	0.000897	0.00395	CcSEcCtD
Clomipramine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000897	0.00395	CcSEcCtD
Clomipramine—Eczema—Riluzole—amyotrophic lateral sclerosis	0.000893	0.00393	CcSEcCtD
Clomipramine—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.000885	0.00389	CcSEcCtD
Clomipramine—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.000885	0.0172	CbGeAlD
Clomipramine—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00376	CcSEcCtD
Clomipramine—HTR6—nervous system—amyotrophic lateral sclerosis	0.000846	0.0165	CbGeAlD
Clomipramine—Thirst—Riluzole—amyotrophic lateral sclerosis	0.000843	0.00371	CcSEcCtD
Clomipramine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000833	0.00366	CcSEcCtD
Clomipramine—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.000829	0.00365	CcSEcCtD
Clomipramine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.000822	0.00362	CcSEcCtD
Clomipramine—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.000817	0.0159	CbGeAlD
Clomipramine—HTR6—central nervous system—amyotrophic lateral sclerosis	0.000815	0.0159	CbGeAlD
Clomipramine—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000803	0.00353	CcSEcCtD
Clomipramine—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000803	0.00353	CcSEcCtD
Clomipramine—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000803	0.00353	CcSEcCtD
Clomipramine—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00348	CcSEcCtD
Clomipramine—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00348	CcSEcCtD
Clomipramine—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.000784	0.00345	CcSEcCtD
Clomipramine—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.000779	0.0152	CbGeAlD
Clomipramine—HRH2—nervous system—amyotrophic lateral sclerosis	0.000774	0.0151	CbGeAlD
Clomipramine—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00336	CcSEcCtD
Clomipramine—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.000763	0.00336	CcSEcCtD
Clomipramine—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00335	CcSEcCtD
Clomipramine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000755	0.00332	CcSEcCtD
Clomipramine—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000746	0.00328	CcSEcCtD
Clomipramine—HRH2—central nervous system—amyotrophic lateral sclerosis	0.000745	0.0145	CbGeAlD
Clomipramine—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000744	0.0145	CbGeAlD
Clomipramine—GSTP1—medulla oblongata—amyotrophic lateral sclerosis	0.000742	0.0144	CbGeAlD
Clomipramine—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.000733	0.00322	CcSEcCtD
Clomipramine—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00073	0.00321	CcSEcCtD
Clomipramine—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000725	0.00319	CcSEcCtD
Clomipramine—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00071	0.00312	CcSEcCtD
Clomipramine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000708	0.00311	CcSEcCtD
Clomipramine—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000694	0.00305	CcSEcCtD
Clomipramine—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000667	0.00293	CcSEcCtD
Clomipramine—GSTP1—spinal cord—amyotrophic lateral sclerosis	0.000661	0.0129	CbGeAlD
Clomipramine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000659	0.0029	CcSEcCtD
Clomipramine—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.000651	0.0127	CbGeAlD
Clomipramine—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000649	0.00285	CcSEcCtD
Clomipramine—HTR6—brain—amyotrophic lateral sclerosis	0.000647	0.0126	CbGeAlD
Clomipramine—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000641	0.00282	CcSEcCtD
Clomipramine—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000639	0.00281	CcSEcCtD
Clomipramine—Trifluoperazine—SIGMAR1—amyotrophic lateral sclerosis	0.000637	0.251	CrCbGaD
Clomipramine—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000633	0.00279	CcSEcCtD
Clomipramine—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000631	0.00278	CcSEcCtD
Clomipramine—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000628	0.00276	CcSEcCtD
Clomipramine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000622	0.00274	CcSEcCtD
Clomipramine—Depression—Riluzole—amyotrophic lateral sclerosis	0.000617	0.00271	CcSEcCtD
Clomipramine—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00061	0.00268	CcSEcCtD
Clomipramine—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00267	CcSEcCtD
Clomipramine—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00267	CcSEcCtD
Clomipramine—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000603	0.00265	CcSEcCtD
Clomipramine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000601	0.00264	CcSEcCtD
Clomipramine—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000593	0.00261	CcSEcCtD
Clomipramine—HRH2—brain—amyotrophic lateral sclerosis	0.000591	0.0115	CbGeAlD
Clomipramine—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00059	0.00259	CcSEcCtD
Clomipramine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000585	0.00257	CcSEcCtD
Clomipramine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000583	0.00257	CcSEcCtD
Clomipramine—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00058	0.0113	CbGeAlD
Clomipramine—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00058	0.00255	CcSEcCtD
Clomipramine—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000577	0.00254	CcSEcCtD
Clomipramine—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000565	0.00249	CcSEcCtD
Clomipramine—GSTP1—nervous system—amyotrophic lateral sclerosis	0.000557	0.0108	CbGeAlD
Clomipramine—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000557	0.00245	CcSEcCtD
Clomipramine—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000555	0.00244	CcSEcCtD
Clomipramine—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00243	CcSEcCtD
Clomipramine—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00243	CcSEcCtD
Clomipramine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000551	0.00242	CcSEcCtD
Clomipramine—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00055	0.0107	CbGeAlD
Clomipramine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000548	0.00241	CcSEcCtD
Clomipramine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000546	0.0024	CcSEcCtD
Clomipramine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000544	0.00239	CcSEcCtD
Clomipramine—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.000543	0.0106	CbGeAlD
Clomipramine—GSTP1—central nervous system—amyotrophic lateral sclerosis	0.000536	0.0104	CbGeAlD
Clomipramine—GSTP1—cerebellum—amyotrophic lateral sclerosis	0.000524	0.0102	CbGeAlD
Clomipramine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000519	0.00228	CcSEcCtD
Clomipramine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000515	0.00227	CcSEcCtD
Clomipramine—HTR2A—embryo—amyotrophic lateral sclerosis	0.000511	0.00995	CbGeAlD
Clomipramine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000504	0.00222	CcSEcCtD
Clomipramine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000502	0.00221	CcSEcCtD
Clomipramine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0005	0.0022	CcSEcCtD
Clomipramine—Chills—Riluzole—amyotrophic lateral sclerosis	0.000498	0.00219	CcSEcCtD
Clomipramine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000496	0.00218	CcSEcCtD
Clomipramine—Amitriptyline—SIGMAR1—amyotrophic lateral sclerosis	0.000494	0.195	CrCbGaD
Clomipramine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000491	0.00216	CcSEcCtD
Clomipramine—HTR2C—nervous system—amyotrophic lateral sclerosis	0.000489	0.00952	CbGeAlD
Clomipramine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000486	0.00214	CcSEcCtD
Clomipramine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000483	0.00213	CcSEcCtD
Clomipramine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000476	0.0021	CcSEcCtD
Clomipramine—Tension—Riluzole—amyotrophic lateral sclerosis	0.000474	0.00209	CcSEcCtD
Clomipramine—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000473	0.00208	CcSEcCtD
Clomipramine—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.000471	0.00917	CbGeAlD
Clomipramine—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000469	0.00207	CcSEcCtD
Clomipramine—HTR2A—brainstem—amyotrophic lateral sclerosis	0.000468	0.00912	CbGeAlD
Clomipramine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000468	0.00206	CcSEcCtD
Clomipramine—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000465	0.00204	CcSEcCtD
Clomipramine—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.000464	0.00903	CbGeAlD
Clomipramine—HTR2B—nervous system—amyotrophic lateral sclerosis	0.000459	0.00894	CbGeAlD
Clomipramine—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000453	0.00199	CcSEcCtD
Clomipramine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000448	0.00197	CcSEcCtD
Clomipramine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000447	0.00197	CcSEcCtD
Clomipramine—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.000446	0.00869	CbGeAlD
Clomipramine—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000444	0.00195	CcSEcCtD
Clomipramine—HTR2B—central nervous system—amyotrophic lateral sclerosis	0.000442	0.00861	CbGeAlD
Clomipramine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000436	0.00192	CcSEcCtD
Clomipramine—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00191	CcSEcCtD
Clomipramine—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000433	0.00191	CcSEcCtD
Clomipramine—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000433	0.0019	CcSEcCtD
Clomipramine—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00188	CcSEcCtD
Clomipramine—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000427	0.0083	CbGeAlD
Clomipramine—GSTP1—brain—amyotrophic lateral sclerosis	0.000426	0.00829	CbGeAlD
Clomipramine—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000425	0.00187	CcSEcCtD
Clomipramine—Cough—Riluzole—amyotrophic lateral sclerosis	0.000422	0.00186	CcSEcCtD
Clomipramine—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000419	0.00184	CcSEcCtD
Clomipramine—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000417	0.00184	CcSEcCtD
Clomipramine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000412	0.00181	CcSEcCtD
Clomipramine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000412	0.00181	CcSEcCtD
Clomipramine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000412	0.00181	CcSEcCtD
Clomipramine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00041	0.0018	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000409	0.0018	CcSEcCtD
Clomipramine—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.000408	0.00795	CbGeAlD
Clomipramine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000407	0.00179	CcSEcCtD
Clomipramine—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000402	0.00177	CcSEcCtD
Clomipramine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000398	0.00175	CcSEcCtD
Clomipramine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000394	0.00174	CcSEcCtD
Clomipramine—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000394	0.00174	CcSEcCtD
Clomipramine—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.000393	0.00765	CbGeAlD
Clomipramine—Shock—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00171	CcSEcCtD
Clomipramine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000387	0.0017	CcSEcCtD
Clomipramine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000386	0.0017	CcSEcCtD
Clomipramine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000385	0.00169	CcSEcCtD
Clomipramine—ADRA2A—medulla oblongata—amyotrophic lateral sclerosis	0.000384	0.00748	CbGeAlD
Clomipramine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000383	0.00169	CcSEcCtD
Clomipramine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000381	0.00168	CcSEcCtD
Clomipramine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000376	0.00165	CcSEcCtD
Clomipramine—HTR2C—brain—amyotrophic lateral sclerosis	0.000374	0.00728	CbGeAlD
Clomipramine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000369	0.00162	CcSEcCtD
Clomipramine—ALB—brain—amyotrophic lateral sclerosis	0.000365	0.0071	CbGeAlD
Clomipramine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000359	0.00158	CcSEcCtD
Clomipramine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000357	0.00157	CcSEcCtD
Clomipramine—SLC6A4—brain—amyotrophic lateral sclerosis	0.000354	0.0069	CbGeAlD
Clomipramine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000354	0.00156	CcSEcCtD
Clomipramine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00155	CcSEcCtD
Clomipramine—HTR2B—brain—amyotrophic lateral sclerosis	0.000351	0.00684	CbGeAlD
Clomipramine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000351	0.00154	CcSEcCtD
Clomipramine—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000347	0.00153	CcSEcCtD
Clomipramine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000343	0.00151	CcSEcCtD
Clomipramine—ADRA2A—spinal cord—amyotrophic lateral sclerosis	0.000342	0.00667	CbGeAlD
Clomipramine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000341	0.0015	CcSEcCtD
Clomipramine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00034	0.0015	CcSEcCtD
Clomipramine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000337	0.00148	CcSEcCtD
Clomipramine—Pain—Riluzole—amyotrophic lateral sclerosis	0.000337	0.00148	CcSEcCtD
Clomipramine—ABCB1—embryo—amyotrophic lateral sclerosis	0.000335	0.00652	CbGeAlD
Clomipramine—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000327	0.00636	CbGeAlD
Clomipramine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000325	0.00143	CcSEcCtD
Clomipramine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00142	CcSEcCtD
Clomipramine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000313	0.00138	CcSEcCtD
Clomipramine—SLC6A2—brain—amyotrophic lateral sclerosis	0.000312	0.00607	CbGeAlD
Clomipramine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00137	CcSEcCtD
Clomipramine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00137	CcSEcCtD
Clomipramine—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.000291	0.00567	CbGeAlD
Clomipramine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000291	0.00128	CcSEcCtD
Clomipramine—ADRA2A—nervous system—amyotrophic lateral sclerosis	0.000289	0.00562	CbGeAlD
Clomipramine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000283	0.00125	CcSEcCtD
Clomipramine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000279	0.00123	CcSEcCtD
Clomipramine—ADRA2A—central nervous system—amyotrophic lateral sclerosis	0.000278	0.00541	CbGeAlD
Clomipramine—ADRA2A—cerebellum—amyotrophic lateral sclerosis	0.000272	0.00529	CbGeAlD
Clomipramine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00027	0.00119	CcSEcCtD
Clomipramine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00115	CcSEcCtD
Clomipramine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000251	0.0011	CcSEcCtD
Clomipramine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000249	0.00109	CcSEcCtD
Clomipramine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000248	0.00109	CcSEcCtD
Clomipramine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000247	0.00109	CcSEcCtD
Clomipramine—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000245	0.00478	CbGeAlD
Clomipramine—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000236	0.0046	CbGeAlD
Clomipramine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000234	0.00103	CcSEcCtD
Clomipramine—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000231	0.00449	CbGeAlD
Clomipramine—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000227	0.00442	CbGeAlD
Clomipramine—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000224	0.00435	CbGeAlD
Clomipramine—ADRA2A—brain—amyotrophic lateral sclerosis	0.000221	0.00429	CbGeAlD
Clomipramine—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000219	0.00426	CbGeAlD
Clomipramine—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000215	0.00419	CbGeAlD
Clomipramine—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000214	0.00417	CbGeAlD
Clomipramine—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.00021	0.00409	CbGeAlD
Clomipramine—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000191	0.00371	CbGeAlD
Clomipramine—HTR2A—brain—amyotrophic lateral sclerosis	0.000188	0.00365	CbGeAlD
Clomipramine—CYP2D6—brain—amyotrophic lateral sclerosis	0.000171	0.00333	CbGeAlD
Clomipramine—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000161	0.00313	CbGeAlD
Clomipramine—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000155	0.00301	CbGeAlD
Clomipramine—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000151	0.00295	CbGeAlD
Clomipramine—ABCB1—brain—amyotrophic lateral sclerosis	0.000123	0.00239	CbGeAlD
Clomipramine—HTR6—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.18e-05	0.000919	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.18e-05	0.000916	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.18e-05	0.000916	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.15e-05	0.000906	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.15e-05	0.000906	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	2.13e-05	0.000899	CbGpPWpGaD
Clomipramine—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	2.12e-05	0.000895	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.11e-05	0.00089	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	2.11e-05	0.000889	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.1e-05	0.000885	CbGpPWpGaD
Clomipramine—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.09e-05	0.000879	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	2.07e-05	0.000874	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.05e-05	0.000865	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	2.04e-05	0.00086	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	2.03e-05	0.000853	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	2.03e-05	0.000853	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.02e-05	0.000852	CbGpPWpGaD
Clomipramine—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	2.02e-05	0.000849	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	2.01e-05	0.000849	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	2.01e-05	0.000848	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	2.01e-05	0.000846	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.99e-05	0.000839	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.97e-05	0.000829	CbGpPWpGaD
Clomipramine—HTR2A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	1.97e-05	0.000829	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	1.97e-05	0.000829	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	1.97e-05	0.000828	CbGpPWpGaD
Clomipramine—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	1.96e-05	0.000826	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.94e-05	0.000817	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.93e-05	0.000813	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.91e-05	0.000806	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.91e-05	0.000803	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.91e-05	0.000803	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.88e-05	0.00079	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.87e-05	0.000789	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.86e-05	0.000782	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.85e-05	0.00078	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.83e-05	0.00077	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	1.83e-05	0.00077	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.8e-05	0.000759	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.79e-05	0.000753	CbGpPWpGaD
Clomipramine—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	1.77e-05	0.000747	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	1.76e-05	0.000742	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—SOD1—amyotrophic lateral sclerosis	1.75e-05	0.000739	CbGpPWpGaD
Clomipramine—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.73e-05	0.000728	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.72e-05	0.000726	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.72e-05	0.000724	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	1.72e-05	0.000723	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	1.72e-05	0.000723	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.71e-05	0.000721	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	1.71e-05	0.00072	CbGpPWpGaD
Clomipramine—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.71e-05	0.000718	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PLB1—amyotrophic lateral sclerosis	1.7e-05	0.000718	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.7e-05	0.000716	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.7e-05	0.000714	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.69e-05	0.000713	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.66e-05	0.0007	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	1.64e-05	0.00069	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.62e-05	0.000682	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.61e-05	0.000679	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.61e-05	0.000677	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.6e-05	0.000674	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	1.59e-05	0.000671	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—APOE—amyotrophic lateral sclerosis	1.58e-05	0.000663	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	1.57e-05	0.000662	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—GSR—amyotrophic lateral sclerosis	1.57e-05	0.000662	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	1.57e-05	0.000661	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.57e-05	0.000659	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.56e-05	0.000657	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.56e-05	0.000656	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.55e-05	0.000655	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	1.55e-05	0.000655	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.55e-05	0.000653	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.51e-05	0.000636	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.49e-05	0.000625	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.47e-05	0.00062	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.46e-05	0.000617	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.46e-05	0.000615	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.42e-05	0.0006	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.42e-05	0.000596	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.4e-05	0.000588	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	1.38e-05	0.000583	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.38e-05	0.000582	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.38e-05	0.00058	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	1.37e-05	0.000578	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.37e-05	0.000577	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.37e-05	0.000576	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.36e-05	0.000571	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.35e-05	0.000569	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	1.34e-05	0.000566	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.34e-05	0.000564	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.34e-05	0.000563	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.32e-05	0.000558	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.32e-05	0.000558	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CHAT—amyotrophic lateral sclerosis	1.29e-05	0.000544	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.28e-05	0.000537	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.27e-05	0.000535	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.27e-05	0.000535	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.25e-05	0.000527	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	1.24e-05	0.000523	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.24e-05	0.000523	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.24e-05	0.000523	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	1.24e-05	0.000523	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.23e-05	0.000518	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.21e-05	0.00051	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	1.21e-05	0.000508	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.2e-05	0.000505	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.2e-05	0.000504	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.2e-05	0.000503	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.19e-05	0.0005	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.18e-05	0.000496	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.16e-05	0.00049	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.14e-05	0.000481	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.14e-05	0.00048	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.13e-05	0.000476	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.13e-05	0.000474	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.11e-05	0.000469	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.11e-05	0.000468	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.11e-05	0.000468	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.09e-05	0.00046	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.09e-05	0.00046	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.09e-05	0.000458	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.08e-05	0.000455	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.08e-05	0.000455	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.07e-05	0.00045	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.07e-05	0.00045	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.06e-05	0.000446	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.06e-05	0.000445	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.05e-05	0.000443	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.04e-05	0.000438	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.02e-05	0.000431	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	1.02e-05	0.000429	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	0.000427	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.01e-05	0.000425	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.92e-06	0.000418	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.83e-06	0.000414	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	9.75e-06	0.000411	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	9.66e-06	0.000407	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	9.58e-06	0.000403	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	9.41e-06	0.000396	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.39e-06	0.000395	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	9.3e-06	0.000392	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.17e-06	0.000386	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	9.15e-06	0.000385	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.03e-06	0.00038	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	8.93e-06	0.000376	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.9e-06	0.000375	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.81e-06	0.000371	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.79e-06	0.00037	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.77e-06	0.000369	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	8.68e-06	0.000366	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	8.44e-06	0.000355	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	8.41e-06	0.000354	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.39e-06	0.000353	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.37e-06	0.000352	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.35e-06	0.000352	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.15e-06	0.000343	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.13e-06	0.000342	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.1e-06	0.000341	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.98e-06	0.000336	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	7.96e-06	0.000335	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.91e-06	0.000333	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.65e-06	0.000322	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.54e-06	0.000318	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.42e-06	0.000312	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.39e-06	0.000311	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.28e-06	0.000307	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	7.26e-06	0.000306	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.18e-06	0.000302	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	7.13e-06	0.0003	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	6.99e-06	0.000294	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.96e-06	0.000293	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.94e-06	0.000292	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.88e-06	0.00029	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.75e-06	0.000284	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	6.7e-06	0.000282	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.63e-06	0.000279	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.5e-06	0.000274	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.38e-06	0.000269	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	6.37e-06	0.000268	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.25e-06	0.000263	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.23e-06	0.000263	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.23e-06	0.000262	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.97e-06	0.000251	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.91e-06	0.000249	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.86e-06	0.000247	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.72e-06	0.000241	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.69e-06	0.00024	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.67e-06	0.000239	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.55e-06	0.000234	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	5.51e-06	0.000232	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	5.5e-06	0.000232	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.48e-06	0.000231	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.33e-06	0.000225	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.31e-06	0.000223	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—TP53—amyotrophic lateral sclerosis	5.28e-06	0.000222	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—APOE—amyotrophic lateral sclerosis	5.25e-06	0.000221	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.18e-06	0.000218	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.03e-06	0.000212	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.92e-06	0.000207	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.82e-06	0.000203	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.8e-06	0.000202	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.8e-06	0.000202	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.71e-06	0.000198	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.59e-06	0.000193	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.53e-06	0.000191	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.52e-06	0.00019	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.52e-06	0.00019	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.46e-06	0.000188	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.41e-06	0.000186	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.39e-06	0.000185	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.38e-06	0.000184	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	4.17e-06	0.000175	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.16e-06	0.000175	CbGpPWpGaD
Clomipramine—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	4.14e-06	0.000174	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.14e-06	0.000174	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.07e-06	0.000171	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.01e-06	0.000169	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.99e-06	0.000168	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.83e-06	0.000161	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	3.72e-06	0.000157	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.72e-06	0.000156	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.63e-06	0.000153	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.63e-06	0.000153	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.6e-06	0.000151	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.53e-06	0.000149	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.52e-06	0.000148	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	3.42e-06	0.000144	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.34e-06	0.000141	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.08e-06	0.00013	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.07e-06	0.000129	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3e-06	0.000126	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.96e-06	0.000125	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.9e-06	0.000122	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	2.9e-06	0.000122	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.84e-06	0.000119	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.81e-06	0.000118	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.79e-06	0.000118	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.72e-06	0.000114	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.64e-06	0.000111	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.6e-06	0.00011	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.55e-06	0.000107	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.49e-06	0.000105	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.37e-06	9.97e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.34e-06	9.87e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.26e-06	9.54e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.24e-06	9.41e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.98e-06	8.36e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.97e-06	8.28e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.79e-06	7.54e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.53e-06	6.45e-05	CbGpPWpGaD
